Frontage Holdings Corp. (HK:1521) has released an update.
Frontage Holdings Corporation has announced the renewal of its Services Framework Agreement set to expire on 31 December 2024, extending it for three years until 31 December 2027. The agreement, which involves providing laboratory and bioequivalence studies services, will be subject to reporting, announcement, and annual review requirements, but is exempt from shareholder approval. This renewal signifies a continuing partnership between Frontage Holdings Corp. and Hangzhou Tigermed, a controlling shareholder and connected person.
For further insights into HK:1521 stock, check out TipRanks’ Stock Analysis page.
